• br Transparency document br Acknowledgments This

  2024-03-20

  

  Transparency document Acknowledgments This work has been supported by the National Eye Institute (NIH) Grant 5R01EY023315-02 (MA). This study was also supported in part by National Center for Research Resources Grant S10RR027926 for the lipid analysis and by James and Jean Culver Vision Discov

• br Drugs with documented pro apoptotic effects on

  2024-03-19

  

  Drugs with documented pro-apoptotic effects on platelets More than 200 drugs are reported to cause thrombocytopenia [5,42]. The concept of platelet apoptosis is relatively new and was only recently evaluated in the context of drug-induced thrombocytopenia [43]. Table 2 lists the drugs presently k

• br Introduction Endothelial progenitor cells EPCs present a

  2024-03-19

  

  Introduction Endothelial progenitor cells (EPCs) present a class of blood cells with an ability to form new blood vessels relying on pre-existing vessels, which contribute to postnatal angiogenesis [1], [2]. A wide range of studies have demonstrated that EPCs play a critical role in angiogenesis

• br Conclusions and perspectives In view of the evidences

  2024-03-19

  

  Conclusions and perspectives In view of the evidences supporting that sphingosine mg MAS receptors mediate the effects of AT1 antagonists (Iwai et al., 2012, Ohshima et al., 2014, Pernomian et al., 2015, Schuchard et al., 2015), the prime targets from the perspectives on future directions in the

• A phase I trial has recently evaluated enzalutamide an

  2024-03-19

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• Sphingolipids such as ceramides and glucosylceramides are an

  2024-03-19

  

  Sphingolipids, such as ceramides and glucosylceramides, are an important class of bioactive lipids. The levels of these lipids change as a function of adipose tissue mass and functionality, and are partially driven by cellular availability of palmitoyl-CoA. Aberrant accumulation of ceramide, glucosy

• Adenosine receptors activate a number

  2024-03-19

  

  Adenosine receptors activate a number of signalling pathways involved in tissue survival including several mitogen-activated protein kinases (Fredholm et al., 2001). The common feature of all adenosine receptors is the positive coupling to ERK1/2, whilst A2B and A3 receptors can also activate the st

• Patients with ADA SCID may experience autoimmune AEs

  2024-03-19

  

  Patients with ADA-SCID may experience autoimmune AEs after SCT (and/or during ERT) that are thought to be related to immune dysregulation prior to achieving complete immune reconstitution. The more common autoimmune manifestations include hemolytic anemia, hypothyroidism, and immune thrombocytopenia

• br Acknowledgements This work was supported by the

  2024-03-19

  

  Acknowledgements This work was supported by the National Key Technology Research and Development Program (2012BAD19B01) and General Financial Grant from the China Postdoctoral Science Foundation (2015M581754). Introduction Cough is one of the most important defensive reflex brought into actio

• Young disease transitioning B Sle mice show partial

  2024-03-18

  

  Young disease-transitioning B6·Sle1 mice show partial loss of leukocyte Axl versus B6 controls (data not shown). Further, BMDM from diseased B6·Sle1.Yaa mice do not express detectable levels of ADAM10 and TACE (ADAM17) but do express basal levels of Axl similar to wild type B6-derived BMDM (Supplem

• br Author contributions br Competing

  2024-03-18

  

  Author contributions Competing interests Transparency document Acknowledgments This research was funded by a TOP ZonMW grant (40-00812-98-10054) to R.O.E., a DFG grant (KR4391/1-1) and IZKF Erlangen grant (J36) to A.K. and supported in part by Centro de Investigación Biomédica en Red de

• Compound was docked into the active site of Aurora

  2024-03-18

  

  Compound was docked into the active site of Aurora B kinase using Tripos sybyl-X ver. 2.1.1. The crystal structure of human Aurora B kinase cocrystallized with its potent inhibitor VX-680 was used for the docking analysis (PDB ID: ). The most likely binding conformations were selected based on the

• Congruously our findings of voltage electrode

  2024-03-18

  

  Congruously, our findings of voltage-electrode-clamping assays indicate that hipN851K mutation mediates partial loss of Na+/K+-ATPase pump currents, also confirming our thesis that hipN851K mutation acts as a hypomorph. As demonstrated here by our external electrical stimulation studies and ECG reco

• Several structural classes of ASK inhibitors mostly from ind

  2024-03-18

  

  Several structural CEP-18770 mg of ASK1 inhibitors, mostly from industry but also from academia, have been identified over the last decade. In 2012, Terao et al. (Takeda) reported imidazo[1,2-α]pyridine () as a potent ASK1 inhibitor derived from structure-based drug design. GSK, Merck and Gilead r

• NBI 27914 hydrochloride The approach of enzymatically conver

  2024-03-18

  

  The approach of enzymatically converting an analyte and detecting it by the resulting small pH changes near the reduced graphene oxide (rGO) surface has successfully been pursued in case of urea (Piccinini et al., 2017). Furthermore, this work reported that electrostatic layer-by-layer (LbL) assembl

16260 records 181/1084 page Previous Next First page 上5页 181182183184185 下5页 Last page